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Abstract
Background In healthy BRCA1/2 mutation carriers, bilateral risk-reducing mastectomy (BRRM) strongly reduces the risk 
of developing breast cancer (BC); however, no clear survival benefit of BRRM over BC surveillance has been reported yet.
Methods In this Dutch multicenter cohort study, we used multivariable Cox models with BRRM as a time-dependent covari-
able to estimate the associations between BRRM and the overall and BC-specific mortality rates, separately for BRCA1 and 
BRCA2 mutation carriers.
Results During a mean follow-up of 10.3 years, 722 out of 1712 BRCA1 (42%) and 406 out of 1145 BRCA2 (35%) muta-
tion carriers underwent BRRM. For BRCA1 mutation carriers, we observed 52 deaths (20 from BC) in the surveillance 
group, and 10 deaths (one from BC) after BRRM. The hazard ratios were 0.40 (95% CI 0.20–0.90) for overall mortality and 
0.06 (95% CI 0.01–0.46) for BC-specific mortality. BC-specific survival at age 65 was 93% for surveillance and 99.7% for 
BRRM. For BRCA2 mutation carriers, we observed 29 deaths (7 from BC) in the surveillance group, and 4 deaths (no BC) 
after BRRM. The hazard ratio for overall mortality was 0.45 (95% CI 0.15–1.36). BC-specific survival at age 65 was 98% 
for surveillance and 100% for BRRM.
Conclusion BRRM was associated with lower mortality than surveillance for BRCA1 mutation carriers, but for BRCA2 muta-
tion carriers, BRRM may lead to similar BC-specific survival as surveillance. Our findings support a more individualized 
counseling based on BRCA mutation type.
Keywords BRCA1/2 · Bilateral risk-reducing mastectomy · Prevention · Surveillance · Survival
Introduction
Women with a germline BRCA1/2 gene mutation have high 
risks of developing breast cancer (BC), estimated to range 
from 45 to 88% for a first BC up to the age of 70 years [1–4]. 
Moreover, BC is diagnosed at a younger age in BRCA1/2 
mutation carriers than in the general population [4–6], with 
an increased risk from the age of 25 years. For healthy 
BRCA1/2 mutation carriers, the options are to follow a 
BC surveillance program aimed at early BC detection, or 
to opt for bilateral risk-reducing mastectomy (BRRM) to 
reduce BC risk. In healthy BRCA1/2 mutation carriers, 
BRRM reduces the risk of BC with estimates even up to 
100% [7–12], and this method may have beneficial effects 
on quality of life by diminishing the strong anxiety of get-
ting BC. However, despite the strong BC risk-reduction, no 
clear survival benefit of BRRM over BC surveillance has 
been reported so far.
Mathematical models with simulated cohorts suggested 
that surveillance with both mammography and magnetic 
resonance imaging (MRI) in combination with risk-reducing 
salpingo-oophorectomy might offer an almost comparable 
survival as BRRM with risk-reducing salpingo-oophorec-
tomy, due to improved imaging techniques and better sys-
temic treatment options in recent years [13–15]. However, 
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no convincing prospective data are available so far. Previ-
ously, we observed better 10-year overall survival in the 
BRRM group than in the surveillance group (99% vs. 96%) 
among 570 healthy BRCA1/2 mutation carriers, but this dif-
ference was not significant [10].
To investigate whether BRRM leads to survival benefit, 
we determined the overall and breast cancer-specific mor-
tality rates among 2857 healthy BRCA1/2 mutation carriers 
opting for either BRRM or surveillance with follow-up until 
2017. Since BRCA2-associated BCs have more favorable 
characteristics than BRCA1-associated BCs [10, 16, 17], and 
BRCA2 mutation carriers have shown lower recurrence rates 
than BRCA1 mutation carriers [10], we performed all analy-
ses for BRCA1 and BRCA2 mutation carriers separately.
Participants and methods
Study population
In the context of the Hereditary Breast and Ovarian Can-
cer Netherlands (HEBON) study, members of breast and/
or ovarian cancer families are being identified through the 
departments of Clinical Genetics/Family Cancer Clinics at 
eight Dutch academic centers and the Netherlands Cancer 
Institute [18]. Written informed consent was obtained from 
each participant, or from a close relative in case of already 
deceased individuals. As of January 1999, relevant data on 
participants, including data on preventive strategies, the 
occurrence of cancer and vital status, were retrieved and 
updated through medical files and questionnaires, and 
through linkages to the Netherlands Cancer Registry, the 
Dutch Pathology Database, and the municipal registry data-
base. The latest follow-up date was December 31, 2016. The 
study was approved by the Medical Ethical Committees of 
all participating centers.
From this national cohort, we identified 5889 germline 
BRCA1/2 mutation carriers. Women were eligible for the 
study if they had no history of cancer—to avoid cancer-
induced testing bias [19, 20]—and had both breasts and both 
ovaries in situ at the date of DNA test result. As shown in 
Fig. 1a, we selected 1712 BRCA1 and 1145 BRCA2 muta-
tion carriers.
Data collection
We retrieved data on type of mutation (i.e., BRCA1 or 
BRCA2) and date of DNA diagnosis; dates of birth, of diag-
noses of first BC, ovarian cancer, and other cancers; dates of 
BRRM and risk-reducing salpingo-oophorectomy; and date 
and cause of death. We also collected data on BC charac-
teristics (size, nodal status, behavior, differentiation grade, 
hormone receptor status, and HER2 status) and BC treat-
ment details.
Breast cancer surveillance for BRCA1/2 mutation 
carriers in the Netherlands
BC surveillance for BRCA1/2 mutation carriers consisted 
of annual imaging by MRI between 25 and 60 years (since 
1998), next to annual imaging by mammography from 30 till 
60 years of age, biennial (annual since 2012) mammography 
from age 60 till age 75, and annual clinical breast examina-
tion from the age of 25 years onward [21]. For the current 
cohort, the actual attendance to the surveillance program 
was derived from self-reported data.
Statistical analyses
We evaluated person characteristics by comparing women 
who opted for BRRM (BRRM group) with women who did 
not until the end of follow-up (surveillance group). Differ-
ences between the BRRM and the surveillance group were 
tested by using χ2 for categorical variables, and the two-
sample Wilcoxon rank-sum (Mann–Whitney) test for con-
tinuous variables.
The outcomes, overall mortality and breast cancer-spe-
cific mortality, were measured in person-years of observa-
tion. We started the observation period at the age at DNA 
test result or 25 years of age (since from this age regular 
BC surveillance is offered to Dutch BRCA1/2 mutation car-
riers), whichever came last. Figure 1b depicts the alloca-
tion of person-years of observation to the BRRM and the 
surveillance group. For women who opted for BRRM and 
had unexpected malignant findings in the mastectomy speci-
mens, we considered BC as being developed before BRRM, 
and therefore we allocated all person-years of observation 
to the surveillance group. The observation period ended at 
the age at last follow-up or death (due to all causes for the 
overall survival analyses and from BC for the breast cancer-
specific analyses). The earliest date of DNA result was Janu-
ary 3, 1995.
To estimate the associations between BRRM and survival 
endpoints, we used extended Cox models with BRRM as a 
time-dependent variable to obtain hazard ratios (HRs) and 
accompanying 95% confidence intervals (CIs), using the sur-
veillance group as the reference. To adjust for potential con-
founders, we generated a propensity score, based on year of 
birth, age at start of observation, age at DNA test result, year 
of DNA test result, and undergoing risk-reducing salpingo-
oophorectomy (yes or no; time dependent) and performed 
multivariable analyses with the propensity score as covari-
able. For the mentioned variables all data were available for 
all participants. To graph the cumulative survival curves for 
the BRRM and the surveillance group, we used the Simon and 
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Makuch method—which takes into account the change in an 
individual’s covariate status over time—with chronological 
age as the time variable [22, 23]. Using the log-rank test for 
equality of survivor functions, we tested whether the curves 
were significantly different from each other. We performed all 
analyses separately for BRCA1 and BRCA2 mutation carriers.
All P values were two-sided, and a significance level 
α = 0.05 was used. Analyses were performed using STATA 
(version 14.1, StataCorp, Collegestation, TX).
Results
Study population
Of the 1712 selected BRCA1 mutation carriers, 722 opted 
for BRRM, and 406 of the 1145 BRCA2 mutation carri-
ers opted for BRRM (Table 1). Women opting for BRRM 
underwent DNA testing at a younger age than women who 
Fig. 1  Flowchart of inclusion 
of participants (a) and Design 
of the analytic method and 
allocation of person-years of 
observation (b). DNA date of 
DNA test result, CE censoring 
event, BRRM bilateral risk-
reducing mastectomy, BC first 
breast cancer. As visualized in 
b, observation started at the 
age at DNA test result, or age 
25, whichever came last. For 
women not opting for BRRM, 
we allocated all person-years 
of observation (PYO) to the 
surveillance group (solid lines; 
scenarios 1, 3, 4, 7). For women 
opting for BRRM, we allocated 
PYO before surgery to the sur-
veillance group, and PYO after 
surgery to the BRRM group 
(dashed lines; scenarios 2, 5, 6, 
and 8). The observation ended 
on the age of death (any cause), 
or age at study closing date (i.e., 
December 31, 2016), whichever 
came first
BRRM
BC
5889 Female BRCA1/2 mutaon carriers available for selecon A
B 
BC
End study/CEDNA/age 25
BC
8 (n=12)
7 (n=46)
6 (n=2)
5 (n=6)
4 (n=35)
3 (n=377)
2 (n=1108)
1 (n=1271)
Death
Death
BRRM
BCBRRM
Death
BRRM Death
Scenario
2908 Excluded
1990 Breast cancer before DNA diagnosis
503 Born before 1940
287 Ovarian cancer before DNA diagnosis
96 Date of DNA test result unknown
18 Date of death unknown
2 Date of risk-reducing salpingo-oophorectomy unknown
6 Date of risk-reducing-mastectomy unknown
4 Breast cancer diagnosed under the age of 25 years
2 Date of birth unknown
2981 Eligible female BRCA1/2 mutaon carriers 
2857 Female BRCA1/2 mutaon carriers eligible for analyses
1712 BRCA1
1145 BRCA2
124 Excluded before the start of observaon
108 Lost to follow-up
16 Died
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Table 1  Characteristics of BRCA1 and BRCA2 mutation carriers at risk of breast cancer
BRRM bilateral risk-reducing mastectomy, IQR interquartile range, RRSO risk-reducing salpingo-oophorectomy, n/N number out of total number 
of women with nonmissing data on the variable of interest, OC ovarian cancer, BC breast cancer, CRRM contralateral risk-reducing mastectomy
a Differences between the BRRM and the surveillance groups were tested by using χ2 for categorical variables, and the two-sample Wilcoxon 
rank-sum (Mann–Whitney) test for continuous variables
b N = 27 found as unexpected malignant finding in the mastectomy specimens of women initially opting for BRRM. Three of these patients died 
during the observation period; two of BC, one of another malignancy
c N = 13 found as unexpected malignant finding in the mastectomy specimens of women initially opting for BRRM. None of these patients died 
BRCA1 mutation carriers BRCA2 mutation carriers
BRRM Surveillance P  valuea BRRM Surveillance P  valuea
N (%) 722 (42%) 990 (58%) 406 (35%) 739 (65%)
Observation period, median years (IQR) 10.6 (7.9–15.4) 9.3 (6.7–13.3) < 0.001 9.9 (7.1–12.5) 8.6 (6.5–11.7) < 0.001
Observation period after BRRM, median 
years (IQR)
8.5 (5.5–12.9) – 7.2 (4.8–10.8) –
Age at start of observation, median years 
(IQR)
34 (29–41) 38 (30–47) < 0.001 36 (29–43) 42 (33–51) < 0.001
DNA test result
 Median age (IQR) 34 (29–41) 38 (30–47) < 0.001 36 (29–43) 42 (33–51) < 0.001
 Median year (IQR) 2006 (2001–2008) 2007 (2003–2009) < 0.001 2006 (2004–2009) 2008 (2004–2010) < 0.001
Year of birth
 1940–1949 16 (2%) 87 (9%) < 0.001 11 (3%) 92 (13%) < 0.001
 1950–1959 96 (13%) 199 (20%) 62 (15%) 170 (23%)
 1960–1969 236 (33%) 288 (29%) 128 (32%) 210 (28%)
 1970–1979 268 (37%) 242 (24%) 140 (34%) 177 (24%)
 > 1980 106 (15%) 174 (18%) 65 (16%) 90 (12%)
Median (IQR) 1970 (1963–1976) 1967 (1958–1975) 0.002 1970 (1962–1977) 1966 (1955–1974) < 0.001
BRRM 722 (100%) – 406 (100%) –
Median age (IQR) 37 (32–43) – 38 (33–45) –
Median year (IQR) 2008 (2003–2011) – 2009 (2006–2012) –
RRSO, n/N (%) 557/722 (77%) 569/990 (57%) < 0.001 293/406 (72%) 441/739 (60%) < 0.001
Median age (IQR) 40 (37–44) 44 (40–51) < 0.001 42 (39–48) 47 (42–55) < 0.001
Median year (IQR) 2008 (2004–2011) 2008 (2005–2011) 0.849 2009 (2006–2011) 2009 (2006–2011) 0.535
Before/with/after BRRM 258/64/235 – 146/22/125 –
Breast cancer, n/N (%) 8/722 (1%) 268/990 (27%)b < 0.001 0/406 (0%) 144/739 (19%)c < 0.001
Median age (IQR) 45 (34–48) 44 (35–50) 0.781 – 48 (39–55) NA
Median year (IQR) 2010 (2006–2012) 2009 (2005–2011) 0.953 – 2010 (2007–2013) NA
Median years after BRRM (IQR) 4.4 (1.0–6.6) – – –
CRRM after breast cancer – 172 (17%) – 97 (13%)
Ovarian cancer, n/N (%) 16/722 (2%) 34/990 (3%) 0.139 4/406 (1%) 15/739 (2%) 0.186
Median age (IQR) 45 (38–53) 50 (43–56) 0.169 45 (39–52) 54 (51–63) 0.072
Median year (IQR) 2006 (2002–2011) 2008 (2003–2011) 0.392 2013 (2011–2015) 2009 (2007–2011) 0.063
Before/after BRRM 8/8 – 1/3 –
Other tumor (no OC or BC), n/N (%) 47/722 (7%) 67/990 (7%) 0.833 23/406 (6%) 66/739 (9%) 0.048
Median age (IQR) 47 (39–53) 54 (42–62) 0.005 47 (36–50) 52 (41–62) 0.009
Before/after BRRM 16/31 – 7/16 –
Death (all causes), n/N (%) 10/722 (1%) 52/990 (5%) < 0.001 4/406 (1%) 29/739 (4%) 0.004
Median age (IQR) 53 (47–63) 53 (44–58) 0.293 55 (52–58) 61 (52–67) 0.205
Median year (IQR) 2014 (2011–2015) 2009 (2006–2013) 0.011 2011 (2009–2014) 2011 (2009–2014) 0.846
Cause of  deathd, n/N (%)
 Breast cancer 1/10 (10%) 20/52 (38%) 0.241 0/4 (0%) 7/29 (24%) 0.635
 Ovarian cancer 5/10 (50%) 19/52 (37%) 0/4 (0%) 2/29 (7%)
 Other malignancy 4/10 (40%)e 13/52 (25%)f 3/4 (75%)g 15/29 (52%)h
 Not due to malignancy 0/10 (0%) 0/52 (0%) 1/4 (25%) 5/29 (17%)
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stayed under surveillance until end of follow-up (median 
age 34 vs. 38 for BRCA1, and 36 vs. 42 for BRCA2 muta-
tion carriers). Also, women in the BRRM group more 
often opted for risk-reducing salpingo-oophorectomy 
than women in the surveillance group [557 (77%) vs. 569 
(57%) for BRCA1, and 293 (72%) vs. 441 (60%) for BRCA2 
mutation carriers] at a younger age (median age 40 vs. 44 
for BRCA1, and 42 vs. 47 for BRCA2 mutation carriers; 
Table 1).
Breast cancer
BC occurrence (including both invasive and ductal car-
cinoma in situ) was lower in the BRRM than in the sur-
veillance group [8 (1%) vs. 268 (27%) for BRCA1, and 0 
(0%) vs. 144 (19%) for BRCA2 mutation carriers; Table 1]. 
Among BRCA1 mutation carriers, we observed no differ-
ences in tumor characteristics of BCs occurring after BRRM 
and during surveillance (see Supplementary Table S1).
As shown in Table 2, BRCA2-associated BCs were diag-
nosed with more favorable characteristics than BRCA1-asso-
ciated BCs, i.e., diagnosed at older age, more often in situ, 
better differentiated, and less often showing a triple-negative 
phenotype. Consequently, BRCA2 mutation carriers were 
less often treated with chemotherapy, and more often treated 
with endocrine therapy.
Overall mortality
All-cause mortality rates were lower for women opting for 
BRRM than for women under surveillance (Table 3). For 
BRCA1 mutation carriers, the multivariable Cox model 
yielded an HR of 0.40 (95% CI 0.20–0.80) in favor of the 
BRRM group. The unadjusted survival curves showed a 
probability of being alive at 65 years of 93% for the BRRM 
group and 83% for the surveillance group (Fig. 2a). For 
BRCA2 mutation carriers, the multivariable HR was 0.45 
(95% CI 0.15–1.36) (Table 3), and the probability of being 
alive at the age of 65 was 93% the BRRM group, and 90% 
for the surveillance group (Fig. 2b).
Breast cancer‑specific mortality
Breast cancer-specific mortality rates were lower for 
women opting for BRRM than for women under surveil-
lance (Table 3). Eventually, one BRCA1 (0.1%) and no 
BRCA2 mutation carriers died due to BC after BRRM, 
while from the surveillance group 20 BRCA1 (2.0%) and 7 
BRCA2 (0.9%) mutation carriers died due to BC. For BRCA1 
mutation carriers, the multivariable HR was 0.06 (95% CI 
0.01–0.46) in favor of the BRRM group. At the age of 65, 
the probability of not having died due to BC was 99.7% 
for the BRRM group and 93% for the surveillance group 
(Fig. 2c). For BRCA2 mutation carriers, no HR could be 
estimated, as not one woman opting for BRRM died due 
to BC (Table 3). The probability of not having died due to 
BC at the age of 65 was 100% in the BRRM and 98% in the 
surveillance group (Fig. 2d).
Discussion
In this nationwide cohort study, we observed lower overall 
and breast cancer-specific mortality rates among BRCA1 
mutation carriers opting for BRRM than among those under 
surveillance. For BRCA2 mutation carriers, BRRM was non-
significantly associated with lower overall mortality when 
compared with surveillance. Not one BRCA2 mutation car-
rier died of BC after BRRM, while the surveillance group 
performed almost as good. In addition, BRCA2-associated 
BCs were diagnosed less frequently, and had more favorable 
characteristics than BRCA1-associated BCs.
All analyses were performed separately for BRCA1 
and BRCA2 mutation carriers, which is more accurate 
because BRCA1-associated BCs and BRCA2-associated 
BCs represent different entities. The current results are in 
line with our previous observation of a small but nonsig-
nificant better 10-year overall survival after BRRM than 
under surveillance (99% vs. 96%) for a smaller combined 
cohort of BRCA1/2 mutation carriers [10]. The observa-
tion that BRRM was associated with lower breast cancer-
specific mortality for BRCA1 mutation carriers, and not for 
BRCA2 mutation carriers underscores that counseling for 
during the observation period
d Retrieved from the Netherlands Cancer Registry (44%) or derived from the available data on recurrent disease and ages at cancer diagnoses and 
death (56%)
e Stomach (N = 1), pancreas (N = 2), lymph nodes (N = 1)
f Esophagus (N = 1), rectum/rectosigmoid (N = 2), bialiary tract (N = 1), pancreas (N = 2), lung (N = 3), bone marrow (N = 1), skin (N = 1), brain 
(N = 1), unknown primary site (N = 1)
g Pancreas (N = 2), lung (N = 1)
h Colon (N = 2), bialiary tract (N = 1), pancreas (N = 7), lung (N = 3), skin (N = 1), bladder (N = 1)
Table 1  (continued)
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BRCA1 and BRCA2 mutation carriers regarding the choice 
between risk-reducing mastectomy and surveillance might 
be tailored, although confirmation in a larger cohort of 
especially BRCA2 mutation carriers is warranted.
To the best of our knowledge, this is the first cohort 
study comparing BRRM with surveillance with respect to 
survival in healthy BRCA1 and BRCA2 mutation carriers 
separately. Previous investigations have shown that BRRM 
Table 2  BRCA1- and BRCA2-
associated breast cancer 
characteristics and therapy
IQR interquartile range; n/N number out of total number of women with nonmissing data on the variable of 
interest, ER estrogen receptor, PR progesterone receptor
a Differences between BRCA1- and BRCA2-associated breast cancers were tested by using χ2 for categorical 
variables, and the two-sample Wilcoxon rank-sum (Mann–Whitney) test for continuous variables
b All diagnosed in the surveillance groups
c Hormone receptors were considered positive if staining was seen in ≥ 10% of the nuclei, according to the 
Dutch national guidelines for breast cancer treatment
d Her2 receptor status was scored according to international guidelines. An equivocal immunohistochemical 
result (2+) was followed by fluorescence in situ hybridization
e ER-negative, PR-negative, and Her2-negative
Germline gene mutation
BRCA1 BRCA2 P  valuea
N 276 (16%) 144 (13%) 0.009
Age at diagnosis, median (IQR) 44 (35–50) 48 (39–55) < 0.001
Detection, n/N (%)
 Symptoms 30/121 (25%) 11/46 (24%) 0.607
 Screen-detected 77/121 (63%) 27/46 (59%)
 Detected between 2 screening rounds 14/121 (12%) 8/46 (17%)
Behavior, n/N (%)
 In  situb 32/270 (12%) 36/143 (25%) 0.001
 Invasive 238/270 (88%) 107/143 (75%)
Bloom and Richardson differentiation grade, n/N (%)
 I 9/251 (3%) 11/126 (9%) < 0.001
 II 57/251 (23%) 68/126 (54%)
 III 185/251 (74%) 47/126 (37%)
pT-status, n/N (%)
 0 (in situ) 32/253 (13%) 36/136 (26%) 0.001
 1 163/253 (64%) 79/136 (58%)
 2 58/253 (23%) 19/136 (14%)
 3 0/253 (0%) 2/136 (2%)
pN-status, n/N (%)
 0 207/248 (84%) 100/129 (78%) 0.164
 1 33/248 (13%) 25/129 (19%)
 2 6/248 (2%) 1/129 (1%)
 3 2/248 (1%) 3/129 (2%)
Positive ER-statusc, n/N (%) 49/224 (22%) 79/101 (78%) < 0.001
Positive PR-statusc, n/N (%) 36/219 (16%) 55/100 (55%) < 0.001
Positive Her2-statusd, n/N (%) 10/170 (6%) 8/75 (11%) 0.186
Triple-negativee, n/N (%) 128/166 (77%) 17/75 (23%) < 0.001
Treatment primary breast cancer
 Chemotherapy 170/273 (62%) 56/142 (39%) < 0.001
 Endocrine therapy 42/262 (16%) 51/134 (38%) < 0.001
 Targeted therapy 14/263 (5%) 4/134 (3%) 0.290
 Mastectomy 204/261 (78%) 110/134 (82%) 0.360
 Radiotherapy 64/263 (24%) 38/134 (28%) 0.386
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effectively reduces BC risk [7–12, 24, 25], but convincing 
data regarding survival after BRRM in BRCA1/2 muta-
tion carriers are scarce and mainly derived from modeling 
studies. Using a simulated cohort and Markov modeling 
of outcomes, Grann et al. estimated that BRRM plus risk-
reducing salpingo-oophorectomy at the age of 30 may 
extend survival by 4.9 years over surveillance alone [26]. 
Further, Sigal et al. yielded from their Monte Carlo simu-
lation model gains in life expectancy after BRRM plus 
risk-reducing salpingo-oophorectomy varying from 6.8 to 
10.3 for BRCA1 and 3.4 to 4.4 years for BRCA2 mutation 
carriers [15]. Recently, Giannakeas and Narod showed in 
a simulated cohort that for BRCA mutation carriers who 
underwent bilateral mastectomy at the age of 25, the prob-
ability of being alive at age 80 increased by 8.7% [27]. In 
addition, in an exploratory study in unaffected BRCA1/2 
mutation carriers and untested female first-degree rela-
tives, Ingham et  al. showed overall survival benefit 
of ~ 10% after risk-reducing surgery [28]. However, this 
study is not directly comparable to the current study since 
the authors compared three groups of women undergo-
ing risk-reducing surgery (i.e., BRRM only, risk-reducing 
salpingo-oophorectomy only, or both) with women with-
out any surgery, while we currently incorporated undergo-
ing risk-reducing salpingo-oophorectomy (yes/no) in the 
model. In our opinion, this better reflects daily practice: as 
a result of directive counseling due to ineffective screening 
protocols for early ovarian cancer detection, the uptake 
of risk-reducing salpingo-oophorectomy is high for both 
women undergoing BRRM (~ 75%) and women not (yet) 
opting for BRRM (~ 60%).
For BRCA1 mutation carriers under surveillance, BC 
and ovarian cancer were the main causes of death. The 
high percentage of ovarian cancer deaths in this group—
which was similar to that of BC deaths—emphasizes the 
need for RRSO for BRCA mutation carriers. While in the 
surveillance group 20 out of 990 women (2.0%) died due 
to BC, only one out of 722 women (0.1%) died from BC 
after BRRM. The latter patient was identified with a BRCA1 
mutation at the age of 38, and underwent BRRM 1 year later 
(in 2007). At the age of 42, she was diagnosed with a triple-
negative BC with lung metastases, and died 1 year later. This 
emphasizes—in addition to the fact that eight BCs occurred 
4.4 median years after BRRM in the current cohort—that 
BRRM does not fully protect against the occurrence of BC 
and BC-related death.
Of the 29 deceased BRCA2 mutation carriers in the sur-
veillance group, 24% died of BC, 59% of another malig-
nancy—including two deaths due to ovarian cancer and 
seven due to pancreatic cancer—and 17% died of nonmalig-
nancy-related causes. The higher numbers of non BC-related 
deaths in the surveillance group seem to be coincidental, but 
may explain the higher overall mortality rate though com-
parable breast cancer-specific mortality rate among BRCA2 
mutation carriers under surveillance.
In BRCA2 mutation carriers, we observed no BCs and 
no BC-related deaths after BRRM versus 144 BC cases 
and seven BC-related deaths in the surveillance group, sug-
gesting a maximal risk-reduction of developing BC and 
dying due to BC after BRRM. However, the absolute breast 
cancer-specific survival benefit at the age of 65 was mini-
mal (2%), partly due to the low BC-specific mortality in 
Table 3  Associations of 
bilateral risk-reducing 
mastectomy with all-cause 
mortality and breast cancer-
specific mortality
BRRM bilateral risk-reducing mastectomy, PYO person-years of observation, HR (95% CI), hazard ratio 
(95% confidence interval), BC breast cancer, NA not applicable
a Per 1000 PYO
b Univariable
c Multivariable, adjusted for the estimated propensity score, which was based on year of birth, age at start of 
observation, and undergoing RRSO (yes or no; time dependent)
BRCA1 mutation carriers BRCA2 mutation carriers
BRRM Surveillance BRRM Surveillance
PYO 6647 11,782 3225 7808
All-cause mortality
 Deaths 10 52 4 29
 All-cause mortality rate (95% CI)a 1.5 (0.8–2.8) 4.4 (3.4–5.8) 1.2 (0.4–3.3) 3.7 (2.6–5.3)
 HR (95% CI)b 0.37 (0.19–0.73) 0.52 (0.18–1.50)
 HR (95% CI)c 0.40 (0.20–0.80) 0.45 (0.15–1.36)
Breast cancer-specific mortality
 Deaths due to BC 1 20 0 7
 BC-specific mortality rate (95% CI)a 0.2 (0.02–1.1) 1.7 (1.1–2.6) 0 0.9 (0.4–1.9)
 HR (95% CI)b 0.08 (0.01–0.62) NA
 HR (95% CI)c 0.06 (0.01–0.46) NA
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the surveillance group (i.e., 0.9 per 1000 person-years of 
observation). The latter can be explained by the observa-
tion that BRCA2-associated BCs were diagnosed with more 
favorable characteristics, i.e., diagnosed at older age, more 
often in situ, better differentiated, and less often showing 
a triple-negative phenotype—than BRCA1-associated BCs. 
This supports previous suggestions that BRCA2-associated 
BC patients face a better prognosis than BRCA1-associated 
BC patients [10, 16]. The current results suggest that regard-
ing breast cancer-specific mortality, BC surveillance may be 
a reasonable and balanced alternative to BRRM for BRCA2 
mutation carriers.
The main strengths of the current study are (1) the suf-
ficient numbers of BRCA1 and BRCA2 mutation carriers 
allowing analyses for both groups separately, (2) with long 
enough follow-up, and (3) the availability of data on cause 
of death, enabling to specifically address the ultimate goal 
for BRRM, i.e., breast cancer-specific survival.
This study also has limitations. First, information regard-
ing BC screening modality and frequency was derived from 
self-reported data, and unknown for ~ 50% of the women 
in the surveillance groups. However, we do know that all 
women had been counseled by clinical geneticists and were 
aware of an identified BRCA mutation at the start of the 
observation period. Therefore, we assume that the vast 
majority of the women did participate in a BC surveillance 
program for high-risk women according to Dutch guidelines. 
This assumption is supported by the experience from the 
Rotterdam Family Cancer Clinic that after being positively 
tested for a pathologic mutation in one of the BRCA genes, 
97% of the mutation carriers is yearly screened; 79% of the 
mutation carriers are yearly screened by both MRI and mam-
mography, 11% by MRI only (aged < 30 years), and 7% by 
mammography only (aged > 60 years). Only three percent of 
the proven mutation carriers seem not to attend the national 
screening program for BRCA1/2 mutation carriers, or are 
A
C
B
D
Fig. 2  Overall survival curves for BRCA1 (a) and BRCA2 (b) muta-
tion carriers and breast cancer-specific survival curves for BRCA1 (c) 
and BRCA2 (d) mutation carriers opting for bilateral risk-reducing 
mastectomy (BRRM) versus staying under surveillance, using the 
Simon and Makuch method—which takes into account the change in 
an individual’s variable status over time—with chronological age as 
the time variable
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screened in another hospital (unpublished data). These num-
bers are in line with recently reported international trends 
in the uptake of cancer screening among BRCA1/2 mutation 
carriers [29].
Still, if the BC patients with unknown screening status 
were not under BC surveillance, BCs consequently would 
be diagnosed at a more advanced stage with worse progno-
sis. As a result, the observed number of BC-related deaths 
in the surveillance group could be an overestimation of the 
actual number of BC-related deaths under surveillance, and 
a potential breast cancer-specific survival benefit may be 
overestimated. However, BCs occurring among BRCA1/2 
mutation carriers in the surveillance group with unknown 
screening status showed in fact slightly more favorable char-
acteristics (i.e., more often in situ and smaller than two cen-
timeters; see Supplementary Table S2) than the patients with 
known screening status. In addition, the absolute number of 
women dying from BC was lower among the women with 
unknown screening status: 8 out 864 (0.9%) versus 19 out of 
865 (2.2%) among the women with known screening status 
(P value 0.033; Supplementary Table S2). Thus, it seems 
plausible that the majority of the women with unknown 
screening status were actually under BC surveillance, and 
an overestimation of the observed breast cancer-specific sur-
vival is unlikely.
A second limitation may be that family history is not 
available for all participants. If all women from families 
with high risks of developing BC—usually at young age—
opt for BRRM, this may lead to an overrepresentation of 
women with lower family-based BC risks in the surveillance 
groups. Subsequently, the baseline BC risk and following 
BC-specific mortality may be underestimated in the sur-
veillance groups, leading to an underestimation of potential 
survival benefit after BRRM. However, despite this potential 
underestimation, the study found an association with better 
breast cancer-specific survival for BRCA1 mutation carriers 
after BRRM. Still, as the influence of family history cannot 
be ruled out, it will be interesting to take family history into 
account in future studies.
Thirdly, there might be some bias toward BRRM being 
offered more often to healthier women. This could be sup-
ported by the fact that BRCA2 mutation carriers in the 
surveillance group show more other cancers (i.e., no BC 
or ovarian cancer) than those in the BRRM group (9% vs. 
6%, P = 0.048; Table 1). However, we did not observe this 
difference for BRCA1 mutation carriers, where the inci-
dence of other tumors was 7% for both groups. In addition, 
the median age at diagnosis of cancer other than BC or 
ovarian cancer is higher in the surveillance group than in 
the BRRM group (both for BRCA1 and BRCA2 mutation 
carriers), suggesting that with longer follow-up—and thus 
growing age—the numbers of patients with other tumors 
could increase. Unfortunately, data about health-related 
issues such as weight and past and current smoking habits 
are not available for the current cohort.
In conclusion, BRRM was associated with lower overall 
and breast cancer-specific mortality rates than surveillance 
for BRCA1 mutation carriers. For BRCA2 mutation carri-
ers, BRRM may lead to similar breast cancer-specific sur-
vival as surveillance. The latter is most probably due to the 
more favorable characteristics of BRCA2-associated BCs. 
Therefore, for BRCA2 mutation carriers BC surveillance 
may be as effective as BRRM regarding breast cancer-spe-
cific survival. Although the number of events are small—
especially for the analyses on breast cancer-specific mor-
tality—our findings may support a more individualized 
counseling based on BRCA mutation type regarding the 
difficult choice between BRRM and BC surveillance.
Acknowledgements We thank the Hereditary Breast and Ovarian Can-
cer Research Group Netherlands (HEBON) for providing the data. The 
HEBON consists of the following Collaborating Centers: Netherlands 
Cancer Institute (coordinating center), Amsterdam, NL: M.A. Rookus, 
F.B.L. Hogervorst, F.E. van Leeuwen, M.A. Adank, M.K. Schmidt, 
N.S. Russell, D.J. Jenner; Erasmus Medical Center, Rotterdam, NL: 
J.M. Collée, A.M.W. van den Ouweland, M.J. Hooning, C. Seynaeve, 
C.H.M. van Deurzen, I.M. Obdeijn; Leiden University Medical Center, 
NL: C.J. van Asperen, J.T. Wijnen, R.A.E.M. Tollenaar, P. Devilee, 
T.C.T.E.F. van Cronenburg; Radboud University Nijmegen Medical 
Center, NL: C.M. Kets, A.R. Mensenkamp; University Medical Center 
Utrecht, NL: M.G.E.M. Ausems, R.B. van der Luijt; Amsterdam Medi-
cal Center, NL: C.M. Aalfs, H.E.J. Meijers-Heijboer, T.A.M. van Os; 
VU University Medical Center, Amsterdam, NL: K. van Engelen, J.J.P. 
Gille, Q. Waisfisz; Maastricht University Medical Center, NL: E.B. 
Gómez-Garcia, M.J. Blok; University of Groningen, NL: J.C. Ooster-
wijk, A.H. van der Hout, M.J. Mourits, G.H. de Bock; The Netherlands 
Comprehensive Cancer Organisation (IKNL): S. Siesling, J.Verloop; 
The nationwide network and registry of histo- and cytopathology in 
The Netherlands (PALGA): L.I.H. Overbeek. The HEBON study is 
supported by the Dutch Cancer Society [Grant Nos. NKI1998-1854, 
NKI2004-3088, NKI2007-3756], the Netherlands Organisation of Sci-
entific Research [Grant No. NWO 91109024], the Dutch Pink Ribbon 
foundation [Grant Nos. 110005 and 2014-187.WO76], BBMRI [Grant 
No. NWO 184.021.007/CP46] and Transcan [Grant No. JTC 2012 Can-
cer 12-054]. HEBON thanks the study participants and the registration 
teams of IKNL and PALGA for part of the data collection.
Funding  This work was supported by a Grant from the Dutch Pink 
Ribbon foundation (Grant No. 2016-209).
Compliance with ethical standards 
Conflict of interest The authors declare that they have no conflict of 
interest.
Ethical approval All procedures performed in studies involving human 
participants were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards.
Informed consent Informed consent was obtained from all individual 
participants included in the study, or from a close relative in case of 
already deceased individuals.
732 Breast Cancer Research and Treatment (2019) 177:723–733
1 3
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mour-
its MJ, de Vries J, van der Hout AH, Oosterwijk JC (2010) Pen-
etrance of breast cancer, ovarian cancer and contralateral breast 
cancer in BRCA1 and BRCA2 families: high cancer incidence at 
older age. Breast Cancer Res Treat 124(3):643–651
 2. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans 
DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, 
Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson S, Walker 
L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ, Houghton 
C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, 
Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou 
AC, Easton DF, Embrace (2013) Cancer risks for BRCA1 and 
BRCA2 mutation carriers: results from prospective analysis of 
EMBRACE. J Natl Cancer Inst 105(11):812–822
 3. Brohet RM, Velthuizen ME, Hogervorst FBL, Meijers-Heijboer 
HEJ, Seynaeve C, Collee MJ, Verhoef S, Ausems MGEM, 
Hoogerbrugge N, van Asperen CJ, Garcia EG, Menko F, Ooster-
wijk JC, Devilee P, van’t Veer LJ, van Leeuwen FE, Easton DF, 
Rookus MA, Antoniou AC, Resource H (2014) Breast and ovarian 
cancer risks in a large series of clinically ascertained families with 
a high proportion of BRCA1 and BRCA2 Dutch founder muta-
tions. J Med Genet 51(2):98–107
 4. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij 
TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, 
Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, 
Antoniou AC, Brca, Consortium BC, McGuffog L, Evans DG, 
Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz 
M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, 
Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, 
van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, 
Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, 
Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Fried-
lander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, 
Singer CF, Olah E, Gerdes AM, Arver B, Olsson H (2017) Risks 
of breast, ovarian, and contralateral breast cancer for BRCA1 and 
BRCA2 mutation carriers. JAMA 317(23):2402–2416
 5. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and 
BRCA2 penetrance. J Clin Oncol 25(11):1329–1333
 6. Antoniou AC, Pharoah P, Narod SA, Risch H, Eyfjord J, Hopper 
J, Loman N, Olsson H, Johansson O, Borg A, Pasini B, Radice 
P, Manoukian S, Eccles D, Tang N, Olah E, Anton-Culver H, 
Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thor-
lacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi O-P, 
Thompson D, Evans C, Peto J, Lalloo F, Evans DGR, Easton D 
(2003) Average risks of breast and ovarian cancer associated with 
BRCA1 or BRCA2 mutations detected in case series unselected 
for family history: a combined analysis of 22 studies. Am J Hum 
Genet 72(5):1117–1130
 7. Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg 
CL, Sitta DL, Frost MH, Grant CS, Donohue JH, Woods JE, 
McDonnell SK, Vockley CW, Deffenbaugh A, Couch FJ, Jen-
kins RB (2001) Efficacy of bilateral prophylactic mastectomy in 
BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 
93(21):1633–1637
 8. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van ‘t Veer 
LJ, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly 
MB, Olopade OI, Weber BL (2004) Bilateral prophylactic 
mastectomy reduces breast cancer risk in BRCA1 and BRCA2 
mutation carriers: the PROSE Study Group. J Clin Oncol 
22(6):1055–1062
 9. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, 
Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert 
G, Van T’veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, 
Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, 
Blum JL, Rebbeck TR (2010) Association of risk-reducing sur-
gery in BRCA1 or BRCA2 mutation carriers with cancer risk and 
mortality. J Am Med Assoc 304(9):967–975
 10. Heemskerk-Gerritsen BAM, Menke-Pluijmers MBE, Jager A, 
Tilanus-Linthorst MMA, Koppert LB, Obdeijn IMA, van Deurzen 
CHM, Collee JM, Seynaeve C, Hooning MJ (2013) Substantial 
breast cancer risk reduction and potential survival benefit after 
bilateral mastectomy when compared with surveillance in healthy 
BRCA1 and BRCA2 mutation carriers: a prospective analysis. 
Ann Oncol 24(8):2029–2035
 11. Alaofi R, Nassif M, Al-Hajeili M (2018) Prophylactic mastectomy 
for the prevention of breast cancer: review of the literature. Avi-
cenna J Med 8(3):67–77
 12. Carbine NE, Lostumbo L, Wallace J, Ko H (2018) Risk-reducing 
mastectomy for the prevention of primary breast cancer. Cochrane 
Database Syst Rev 4:CD002748
 13. Kurian AW, Sigal BM, Plevritis SK (2010) Survival analysis of 
cancer risk reduction strategies for BRCA1/2 mutation carriers. J 
Clin Oncol 28(2):222–231
 14. Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke 
L, Mills MA, Plevritis SK (2012) Online tool to guide decisions 
for BRCA1/2 mutation carriers. J Clin Oncol 30(5):497–506
 15. Sigal BM, Munoz DF, Kurian AW, Plevritis SK (2012) A simu-
lation model to predict the impact of prophylactic surgery and 
screening on the life expectancy of BRCA1 and BRCA2 mutation 
carriers. Cancer Epidemiol Biomark Prev 21(7):1066–1077
 16. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouwe-
land A, Menke-Pluymers MB, Bartels CC, Kriege M, van Geel 
AN, Burger CW, Eggermont AM, Meijers-Heijboer H, Klijn JG 
(2007) Tumour characteristics, survival and prognostic factors 
of hereditary breast cancer from BRCA2-, BRCA1- and non-
BRCA1/2 families as compared to sporadic breast cancer cases. 
Eur J Cancer 43(5):867–876
 17. Lakhani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Osin 
PP, McGuffog L, Easton DF, Consortium BCL (2002) The pathol-
ogy of familial breast cancer: predictive value of immunohisto-
chemical markers estrogen receptor, progesterone receptor, HER-
2, and p53 in patients with mutations in BRCA1 and BRCA2. J 
Clin Oncol 20(9):2310–2318
 18. Pijpe A, Manders P, Brohet RM, Collee JM, Verhoef S, Vasen 
HFA, Hoogerbrugge N, van Asperen CJ, Dommering C, Aus-
ems MGEM, Aalfs CM, Gomez-Garcia EB, van’t Veer LJ, van 
Leeuwen FE, Rookus MA (2010) Physical activity and the risk of 
breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res 
Treat 120(1):235–244
 19. Klaren HM, van ‘t Veer LJ, van Leeuwen FE, Rookus MA (2003) 
Potential for bias in studies on efficacy of prophylactic surgery for 
BRCA1 and BRCA2 mutation. J Natl Cancer Inst 95(13):941–947
 20. Heemskerk-Gerritsen BAM, Seynaeve C, van Asperen CJ, Aus-
ems MGEM, Collee JM, van Doorn HC, Garcia EBG, Kets CM, 
van Leeuwen FE, Meijers-Heijboer HEJ, Mourits MJE, van Os 
TAM, Vasen HFA, Verhoef S, Rookus MA, Hooning MJ, Hebon 
(2015) Breast cancer risk after salpingo-oophorectomy in healthy 
BRCA1/2 mutation carriers: revisiting the evidence for risk reduc-
tion. J Natl Cancer Inst 107(5):33. https ://doi.org/10.1093/jnci/
djv10 33
733Breast Cancer Research and Treatment (2019) 177:723–733 
1 3
 21. Dutch breast cancer guidelines (2012). http://www.oncol ine.nl
 22. Simon R, Makuch RW (1984) A non-parametric graphical repre-
sentation of the relationship between survival and the occurrence 
of an event—application to responder versus non-responder bias. 
Stat Med 3(1):35–44
 23. Schultz LR, Peterson EL, Breslau N (2002) Graphing survival 
curve estimates for time-dependent covariates. Int J Methods Psy-
chiatr Res 11(2):68–74
 24. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Log-
mans SC, Seynaeve C, Menke-Pluijmers MB, Bartels CC, Ver-
hoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans 
CT, Klijn JG (2001) Breast cancer after prophylactic bilateral 
mastectomy in women with a BRCA1 or BRCA2 mutation. N 
Engl J Med 345(3):159–164
 25. Skytte AB, Cruger D, Gerster M, Laenkholm AV, Lang C, Bron-
dum-Nielsen K, Andersen MK, Sunde L, Kolvraa S, Gerdes AM 
(2011) Breast cancer after bilateral risk-reducing mastectomy. 
Clin Genet 79(5):431–437
 26. Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, 
Neugut AI (2002) Effect of prevention strategies on survival and 
quality-adjusted survival of women with BRCA1/2 mutations: an 
updated decision analysis. J Clin Oncol 20(10):2520–2529
 27. Giannakeas V, Narod SA (2018) The expected benefit of pre-
ventive mastectomy on breast cancer incidence and mortality in 
BRCA mutation carriers, by age at mastectomy. Breast Cancer 
Res Treat 167(1):263–267
 28. Ingham SL, Sperrin M, Baildam A, Ross GL, Clayton R, Lalloo 
F, Buchan I, Howell A, Evans DG (2013) Risk-reducing surgery 
increases survival in BRCA1/2 mutation carriers unaffected at 
time of family referral. Breast Cancer Res Treat 142(3):611–618
 29. Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino 
WS, Pal T, Lynch HT, Tung NM, Kwong A, Ainsworth P, Karlan 
B, Moller P, Eng C, Weitzel JN, Sun P, Lubinski J, Narod SA, the 
Hereditary Breast Cancer Clinical Study G (2019) International 
trends in the uptake of cancer risk reduction strategies in women 
with a BRCA1 or BRCA2 mutation. Br J Cancer 121(1):15–21. 
https ://doi.org/10.1038/s4141 6-41019 -40446 -41411 
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
Affiliations
Bernadette A. M. Heemskerk‑Gerritsen1  · Agnes Jager1 · Linetta B. Koppert2 · A. Inge‑Marie Obdeijn3 · 
Margriet Collée4 · Hanne E. J. Meijers‑Heijboer5 · Denise J. Jenner6 · Hester S. A. Oldenburg7 · Klaartje van Engelen8 · 
Jakob de Vries9 · Christi J. van Asperen10 · Peter Devilee11 · Marinus J. Blok12 · C. Marleen Kets13 · 
Margreet G. E. M. Ausems14 · Caroline Seynaeve1 · Matti A. Rookus6 · Maartje J. Hooning1
1 Department of Medical Oncology, Erasmus MC 
Cancer Institute, PO Box 5201, 3008 AE Rotterdam, 
The Netherlands
2 Department of Surgery, Erasmus MC Cancer Institute, 
Rotterdam, The Netherlands
3 Department of Radiology, Erasmus MC Cancer Institute, 
Rotterdam, The Netherlands
4 Department of Clinical Genetics, Erasmus MC Cancer 
Institute, Rotterdam, The Netherlands
5 Department of Clinical Genetics, Academic Medical Center, 
Amsterdam, The Netherlands
6 Department of Epidemiology, Netherlands Cancer 
Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, 
The Netherlands
7 Department of Surgery, Netherlands Cancer Institute, 
Amsterdam, The Netherlands
8 Department of Clinical Genetics, VU University Medical 
Center, Amsterdam, The Netherlands
9 Department of Surgery, University Medical Center 
Groningen, Groningen, The Netherlands
10 Department of Clinical Genetics, Leiden University Medical 
Center, Leiden, The Netherlands
11 Department of Human Genetics, Leiden University Medical 
Center, Leiden, The Netherlands
12 Department of Clinical Genetics, Maastricht University 
Medical Center, Maastricht, The Netherlands
13 Department of Human Genetics, Radboud University 
Medical Center, Nijmegen, The Netherlands
14 Department of Medical Genetics, University Medical Center 
Utrecht, Utrecht, The Netherlands
